Candidemia Market

Candidemia Market Overview

The presence of Candida species in the blood of living organisms is known as candidemia. In hospitalized patients, it is found to be the most common fungal bloodstream infection. Candida normally lives on the skin and inside the body, such as the mouth, throat, gut, and vagina without causing any problems. The most common species of Candida is Candida albicans. Among all the growing factors associated with the candidemia market, an upsurge in the prevalence of candidemia disease around the globe is projected to boost the market growth forward. Basilea Pharmaceutica Ltd., Astellas Pharma Inc., and Grupo Ferrer Internacional, S.A. are some of the significant parties in the market for candidemia.

The global candidemia market was valued at USD 3201.9 million in 2023. The market is expected to expand at a CAGR of 3.5% from 2023-2032, and is expected to cross value of USD 4281.5 million by the end of 2032.

Candidemia Market Growth Drivers

Some key drivers for the candidemia market are:

• Rising Prevalence of Candidemia Disease: Candidemia disease is seen to be rising among hospitalized patients due to the species Candida. As the number of hospitalized patients is increasing, therefore the need for treating the disease is also rising.
• Growing Prevalence of Vulvovaginal Candidiasis (VVC) Among Women: It has been observed that VVC is a rising common infection in women. With the growing prevalence of this disease, the demand for candidemia drugs is also expected to grow.
• Increasing Need for Treating Skin Infections: There has been an increase in skin infections in the human body due to the presence of Candida species. Therefore, with the growing prevalence of skin diseases around the globe, the need for medicines for treating these diseases is also estimated to rise.
• Growing Research and Development in the Healthcare Industry: The manufacturers of candidemia drugs are increasing their expenditure on research and development. Therefore, it is an opportunity for market expansion in the coming years.

                                              Get More Insights on This Report - Request Free Sample PDF

Candidemia Market Challenges

Some challenges facing the candidemia market are:

• Manufacturing-Related Regulatory Challenges: The manufacturers of candidemia drugs face several regulatory challenges while manufacturing these drugs. This affects the production of these drugs, ultimately, hampering the demand for these products globally.
• Exports-Related Regulatory Challenges: Different nations worldwide have different regulations set for the trade of pharmaceutical drugs. Due to this, the manufacturers of these drugs could not export these drugs to certain nations, which also limits the market growth.
• Fluctuating Price of Raw Materials: A sudden rise in the price of the raw materials used in the manufacturing of candidemia drugs hampers the demand for the product and in turn growth of the market.

Candidemia Market Segmentation

Segmentation of candidemia market are:

• By Route of Administration
  • Injection
  • Ointment
  • Oral
• By Class of Drugs
  • Polyene
  • Azole
  • Echinocandin
  • Miscellaneous
• By Anatomy
  • Oral
  • Vulvovaginal
  • Cutaneous
  • Invasive
  • Systemic Candidiasis
• By Distribution Channel
  • Hospitals
  • Clinics
  • Retail Pharmacies
  • Drug Store Channel
• By Region:
  • North America (U.S., and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Middle East and Africa

Timeline considered for all these studies will be:

2023 – Base Year

2023 – Estimated Year

2023-2032 – Forecast Period

Candidemia Market Regional Synopsis

The North America candidemia market is projected to hold the largest market share during the forecast period. Rise in research and product development amongst the players, especially in the United States, followed by the presence of several manufacturers of candidemia drugs and the presence of a strong healthcare network in the region are some of the major factors predicted to drive the market growth.

On the other hand, the market for candidemia in Europe is expected to grab a significant market share, supported by the high prevalence of vulvovaginal candidiasis (VVC) amongst women, and the growing awareness for the treatment of these disease amongst the women individuals.

Candidemia Market Key Players

Some key players in the candidemia market are:

• Basilea Pharmaceutica Ltd.
• Astellas Pharma Inc.
• Grupo Ferrer Internacional, S.A.
• Pacgen Life Science Corporation
• NovaDigm Therapautics, Inc.
• Cidara Therapautics, Inc.
• Amplyx Pharmaceuticals Inc.
• Pfizer Inc.
• Wockhardt Limited.
• Ranbaxy (Sun Pharmaceutical Industries Ltd.)
• Bristol Laboratories
• Glenmark Pharmaceuticals
• Taro Pharmaceuticals
• Perrigo Company plc.
• Bayer AG
• Teva Pharmaceuticals
• Stellar Pharma